ITCIIntra-Cellular Therapies, Inc.

Nasdaq intracellulartherapies.com


$ 75.03 $ 0.08 (0.1 %)    

Thursday, 12-Sep-2024 12:33:00 EDT
QQQ $ 469.86 $ 1.23 (0.26 %)
DIA $ 408.98 $ -0.48 (-0.12 %)
SPY $ 555.24 $ 0.26 (0.05 %)
TLT $ 99.95 $ -0.42 (-0.42 %)
GLD $ 235.19 $ 0.55 (0.23 %)
$ 74.72
$ 74.95
-- x --
$ 90.00 x 237
$ 74.95 - $ 75.20
$ 45.50 - $ 84.89
257,185
na
7.9B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-01-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 03-01-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 04-28-2016 03-31-2016 10-Q
35 04-28-2016 03-31-2016 10-Q
36 02-25-2016 12-31-2015 10-K
37 11-05-2015 09-30-2015 10-Q
38 08-05-2015 06-30-2015 10-Q
39 04-30-2015 03-31-2015 10-Q
40 03-12-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-upgrades-intra-cellular-therapies-to-overweight-raises-price-target-to-92

Piper Sandler analyst Charles Duncan upgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Neutral to Overweight and raises t...

 jp-morgan-maintains-overweight-on-intra-cellular-therapies-raises-price-target-to-81

JP Morgan analyst Jessica Fye maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the price target...

 rbc-capital-maintains-outperform-on-intra-cellular-therapies-lowers-price-target-to-106

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and lowers the price t...

 cantor-fitzgerald-maintains-overweight-on-intra-cellular-therapies-raises-price-target-to-130

Cantor Fitzgerald analyst Charles Duncan maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and raises the p...

 ubs-maintains-neutral-on-intra-cellular-therapies-lowers-price-target-to-79

UBS analyst Ashwani Verma maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price target from $...

 goldman-sachs-maintains-neutral-on-intra-cellular-therapies-lowers-price-target-to-74

Goldman Sachs analyst Corinne Jenkins maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and lowers the price t...

 needham-reiterates-buy-on-intra-cellular-therapies-maintains-100-price-target

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

 needham-reiterates-buy-on-intra-cellular-therapies-maintains-100-price-target

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

 intra-cellular-therapies-q2-2024-gaap-eps-016-beats-020-estimate-sales-161400m-beat-157880m-estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate...

 needham-maintains-buy-on-intra-cellular-therapies-raises-price-target-to-100

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $94 t...

 ubs-downgrades-intra-cellular-therapies-to-neutral-lowers-price-target-to-83

UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target ...

 rbc-capital-reiterates-outperform-on-intra-cellular-therapies-maintains-103-price-target

RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and maintains $103 pr...

 chinas-bilibili-and-ollies-bargain-outlet-were-among-10-mid-cap-stocks-with-biggest-gains-in-the-last-week-june-16-june-22-2024-are-they-in-your-portfolio

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION